核医学nuclearmedicine课件.pptVIP

下载本文档

6
0
约9.51千字
约 72页
2018-07-02 发布于贵州
举报
版权申诉

核医学nuclearmedicine课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

核医学nuclearmedicine课件

Principle of PET Imaging Each annihilation produces two 511 keV photons traveling in opposite directions (180O) which are detected by the detectors surrounding the subject G L U T PLASMA TISSUE FDG Fluorodeoxyglucose Metabolism [18F]Fluorodeoxyglucose (FDG) PET Control Alzheimer’s Disease Center for Functional Imaging; Life Sciences Division; Lawrence Berkeley National Laboratory; Berkeley, CA. Brain Metabolism ([18F]FDG) [11C]Raclopride PET Brain Study Normal Cocaine Abuser Courtesy BNL PET Project nCi/cc 1000 800 600 400 200 0 Therapeutic Nuclear Medicine Fission products useful in nuclear medicine include: 99Mo, 131I, 133Xe, 137Cs and 90Sr Mo-99 I-131 Differentiated Thyroid Carcinoma 5 mCi Na131I Imaging Treatment Planning 48 h p.i. Differentiated Thyroid Carcinoma Therapy 105 mCi Na131I 27 h p.i. Differentiated Thyroid Carcinoma Post Surgical Resection Therapy 57Co Flood Source + 105 mCi Na131I Differentiated Thyroid Carcinoma 201TlCl and 99mTc-Sestamibi Imaging 4 months after Na131I Therapy Canine Osteosarcoma Tumor distal radius Story of QuadraMetTM -- I 153Sm identified as a useful nuclide for radiotherapy by MU researchers Development began in early 1980’s at MU in collaboration with the Dow Chemical Company [phosphonate ligand complexes;153Sm-EDTMP] Successful in treatment of primary osteosarcoma in canine patients, with added bonus of 18% cure rate [MU College of Veterinary Medicine] One of Our First Patients Bone Scans of Canine Patient Before Treatment: 8/15/85 After Treatment: 3/3/86 Results of Clinical Trial of153Sm-EDTMP in Canine Osteosarcoma Response # of Dogs (%) Survival (months) Disease Free 7 (18%) 11 - 60 Partial Response 25 (62%) 1 - 16 No Response 8 (20%) 0.5 - 1 Story of QuadraMet? -- II Clinical trials began in late 1980’s, with doses supplied by MURR for Phase I studies ~80% efficacy, with ~25% obtaining full pain remission Approved in U.S. for pain palliation of metastatic bone cancer in March, 1997 153Sm-EDTMP [QuadraMet